

Patient Name: CELEBIOGLU, AYLIN
Patient Address: 19 PANORAMA CRESCENT, MOUNT RIVERVIEW 2774
D.O.B: 7/06/1982 **Gender:** F
Medicare No.: 2539340408 **IHI No.:**
Lab. Reference: 838481429-H-H902 **Provider:** bsp
Addressee: DR CECILIA ROWE **Referred by:** Dr Cecilia Rowe
Date Requested: 29/02/2024 **Date Performed:** 2/03/2024
Date Collected: 2/03/2024 **Complete:** Final
Specimen:
Subject(Test Name): HAEMATOLOGY
Clinical Information:

Clinical Notes : ON MIRENA

HAEMATOLOGY

Date	25/01/23	18/10/23	18/10/23	02/03/24		
Time F-Fast	1449	0819 F	0819 F	1016 F		
Lab ID	884245985	837498927	837498968	838481429	Units	Reference
Haemoglobin	130	121	121	125	g/L	(119-160)
RCC	4.5	4.3	4.3	4.4	x10 ¹² /L	(3.8-5.8)
Haematocrit	0.40	0.38	0.38	0.38		(0.35-0.48)
MCV	89	87	87	87	fL	(80-100)
MCH	28.8	27.9	27.9	28.3	pg	(27.0-32.0)
MCHC	323	320	320	326	g/L	(310-360)
RDW	13.5	12.9	12.9	13.1		(10.0-15.0)
WCC	L 3.7	L 3.5	L 3.5	L 2.6	x10 ⁹ /L	(4.0-11.0)
Neutrophils	2.68	2.08	2.08	L 1.58	x10 ⁹ /L	(2.0-7.5)
Lymphocytes	L 0.50	L 0.41	L 0.41	L 0.45	x10 ⁹ /L	(1.0-4.0)
Monocytes	0.37	0.34	0.34	0.28	x10 ⁹ /L	(0.0-1.0)
Eosinophils	0.11	H 0.63	H 0.63	0.24	x10 ⁹ /L	(0.0-0.5)
Basophils	0.05	0.03	0.03	0.05	x10 ⁹ /L	(0.0-0.3)
NRBC	<1.0	<1.0	<1.0	<1.0	/100 WBC	(<1)
Platelets	216	203	203	205	x10 ⁹ /L	(150-450)

Comments on Collection 02/03/24 1016 F:

Moderate lymphopenia

Mild neutropenia.

Drug effect, viral illness or an autoimmune disorder are possible causes.

NATA Accreditation No 2178

Tests Completed: Glu(p), FBC(e)

Tests Pending : LH(s), FSH(s), Oest(s), Commenting, B12(s), Fol(s), LFT(s),
C(s), UCreat(s), E(s), Lipids HDL(s), Vit D(s), TSH(s)

Sample Pending :

Patient Name: CELEBIOGLU, AYLIN
Patient Address: 19 PANORAMA CRESCENT, MOUNT RIVERVIEW 2774
D.O.B: 7/06/1982
Medicare No.: 2539340408
Lab. Reference: 838481429-C-C141
Addressee: DR CECILIA ROWE
Gender: F
IHI No.:
Provider: bsp
Referred by: Dr Cecilia Rowe
Date Requested: 29/02/2024
Date Collected: 2/03/2024
Specimen:
Subject(Test Name): BIOCHEMISTRY
Clinical Information:

Date Performed: 2/03/2024
Complete: Final

Clinical Notes : ON MIRENA

BIOCHEMISTRY

Date	25/01/23	18/10/23	18/10/23	02/03/24		
Time F-Fast	1449	0819 F	0819 F	1016 F		
Lab ID	884245985	837498927	837498968	838481429	Units	Reference
Status				Fasting		
Sodium	139	139	139	140	mmol/L	(135-145)
Potassium	4.5	4.0	4.0	4.7	mmol/L	(3.5-5.5)
Chloride	104	102	102	101	mmol/L	(95-110)
Bicarbonate	27	28	28	24	mmol/L	(20-32)
Urea	H 7.6	5.7	5.7	6.9	mmol/L	(2.5-7.0)
Creatinine	65	70	70	65	umol/L	(45-85)
eGFR	>90	90	90	>90	mL/min/1.73m2	(>59)
Bili.Total	6	6	6	9	umol/L	(3-15)
ALP	72	69	69	55	U/L	(20-105)
GGT	16	18	18	18	U/L	(5-35)
LD	173	163	163	196	U/L	(120-250)
AST	26	23	23	24	U/L	(10-35)
ALT	25	20	20	17	U/L	(5-30)
Total Protein	76	71	71	76	g/L	(68-85)
Albumin	47	44	44	48	g/L	(37-48)
Globulin	29	27	27	28	g/L	(23-39)
Cholesterol				4.6	mmol/L	(<5.5)
Triglycerides				0.7	mmol/L	(<2.0)

Comments on Collection 02/03/24 1016 F:
 eGFR (mL/min/1.73m2) calculated by CKD-EPI formula - see www.kidney.org.au

NATA Accreditation No 2178

Tests Completed: LFT(s), C(s), UCreat(s), E(s), Glu(p), Lipids HDL(s), FBC(e)
 Tests Pending : LH(s), FSH(s), Oest(s), Commenting, B12(s), Fol(s),
 Vit D(s), TSH(s)
 Sample Pending :

Patient Name: CELEBIOGLU, AYLIN
Patient Address: 19 PANORAMA CRESCENT, MOUNT RIVERVIEW 2774
D.O.B: 7/06/1982 **Gender:** F
Medicare No.: 2539340408 **IHI No.:**
Lab. Reference: 838481429-E-H246 **Provider:** bsp
Addressee: DR CECILIA ROWE **Referred by:** Dr Cecilia Rowe
Date Requested: 29/02/2024 **Date Performed:** 2/03/2024
Date Collected: 2/03/2024 **Complete:** Final
Specimen:
Subject(Test Name): B12/FOLATE/RCF
Clinical Information:

Clinical Notes : ON MIRENA

VIT B12 & FOLATE

Date	02/09/21	26/03/22	25/01/23	02/03/24		
Time F-Fast	1017 F	0922 F	1449	1016 F		
Lab ID	864192056	847455944	884245977	838481429	Units	Reference
Vitamin B12	278		299	324	pmol/L	(135-650)
Active B12	91	108	>128	>128	pmol/L	(>35)
S.Fol (Abbott)		38.5	30.8	30.6	nmol/L	(>7.0)

Comments on Collection 02/03/24 1016 F:
 From 27 November 2023, active B12 (holotranscobalamin) testing will be performed on all patients with low or equivocal (at or below 400 pmol/L) total B12 results. Both tests are eligible for a Medicare rebate under these circumstances.

NATA Accreditation No 2178

Tests Completed: LH(s),FSH(s),B12(s),Fol(s),LFT(s),C(s),UCreat(s),
 E(s),Glu(p),Lipids HDL(s),Vit D(s),TSH(s),
 Active B12(s),FBC(e)
 Tests Pending : Oest(s),Commenting
 Sample Pending :

Patient Name: CELEBIOGLU, AYLIN
 Patient Address: 19 PANORAMA CRESCENT, MOUNT RIVERVIEW 2774
 D.O.B: 7/06/1982
 Medicare No.: 2539340408
 Lab. Reference: 838481429-C-C513
 Addressee: DR CECILIA ROWE
 Gender: F
 IHI No.:
 Provider: bsp
 Referred by: Dr Cecilia Rowe
 Date Requested: 29/02/2024
 Date Collected: 2/03/2024
 Specimen:
 Subject(Test Name): VIT D(S)
 Clinical Information:

Date Performed: 2/03/2024
 Complete: Final

Clinical Notes : ON MIRENA

Date	05/08/22	25/01/23	18/10/23	02/03/24		
Time F-Fast	0824 F	1449	0819 F	1016 F	Units	Reference
Lab ID	298677833	884245985	837498968	838481429		
Vitamin D	73	80	57	88	nmol/L	(50-140)

Comments on Collection 02/03/24 1016 F:
 According to the Position Statement 'Vitamin D and health in adults in Australia and New Zealand' MJA, 196(11):686-687, 2012, Vitamin D status is defined as:

Mild Deficiency	30	-	49 nmol/L
Moderate Deficiency	12.5	-	29 nmol/L
Severe Deficiency	<12.5 nmol/L		

Vitamin D adequacy can be defined as a level >49 nmol/L at the end of winter - the level may need to be 10 - 20 nmol/L higher at the end of summer, to allow for seasonal decrease.
 From 1st November 2014, Medicare rebates for vitamin D testing will apply to patients at risk of Vitamin D deficiency such as chronic lack of sun exposure.

NATA Accreditation No 2178

Tests Completed: LH(s), FSH(s), B12(s), Fol(s), LFT(s), C(s), UCreat(s), E(s), Glu(p), Lipids HDL(s), Vit D(s), TSH(s), Active B12(s), FBC(e)
 Tests Pending : Oest(s), Commenting
 Sample Pending :

Patient Name: CELEBIOGLU, AYLIN
Patient Address: 19 PANORAMA CRESCENT, MOUNT RIVERVIEW 2774
D.O.B: 7/06/1982
Medicare No.: 2539340408
Lab. Reference: 838481429-C-C924
Addressee: DR CECILIA ROWE
Gender: F
IHI No.:
Provider: bsp
Referred by: Dr Cecilia Rowe
Date Requested: 29/02/2024
Date Collected: 2/03/2024
Specimen:
Subject(Test Name): _GLUCOSE
Clinical Information:

Clinical Notes : ON MIRENA

GLUCOSE

Date	02/09/21	26/03/22	25/01/23	02/03/24		
Time F-Fast	1017 F	0922 F	1449	1016 F		
Lab ID	864192056	847455944	884245977	838481429	Units	Reference
F Gluc Plasma	4.6	4.7		5.0	mmol/L	(3.6-6.0)
R Gluc Plasma			5.0		mmol/L	(3.6-7.7)

Comments on Collection 02/03/24 1016 F:
 Diabetes is unlikely if fasting glucose levels are less than 5.5 mmol/L but an OGTT could be indicated in the presence of risk factors such as metabolic syndrome, past gestational diabetes, polycystic ovary or family history of type 2 diabetes.

NATA Accreditation No 2178

Tests Completed: Glu(p), FBC(e)
 Tests Pending : LH(s), FSH(s), Oest(s), Commenting, B12(s), Fol(s), LFT(s), C(s), UCreat(s), E(s), Lipids HDL(s), Vit D(s), TSH(s)
 Sample Pending :

Patient Name: CELEBIOGLU, AYLIN
Patient Address: 19 PANORAMA CRESCENT, MOUNT RIVERVIEW 2774
D.O.B: 7/06/1982 Gender: F
Medicare No.: 2539340408 IHI No.:
Lab. Reference: 838481429-E-B007 Provider: bsp
Addressee: DR CECILIA ROWE Referred by: Dr Cecilia Rowe
Date Requested: 29/02/2024 Date Performed: 2/03/2024
Date Collected: 2/03/2024 Complete: Final
Specimen:
Subject/Test Name: HORMONES
Clinical Information:

Clinical Notes : ON MIRENA

Reproductive Hormones
(Abbott Method)

FSH	88.9	IU/L
LH	26.9	IU/L
Oestradiol	<80	pmol/L

Comment on Lab ID 838481429

FSH	Basal	1.5 - 10
	Mid cycle peak	7.0 - 22
	Post-menopausal	25 - 130

LH	Basal	2.0 - 12
	Mid cycle peak	8.0 - 90
	Post-menopausal	5.0 - 62

Oestradiol	Follicular phase	<320
	Preovulatory phase	450 - 2000
	Luteal phase	125 - 1300
	Post-menopausal	<170

Combined results consistent with ovarian hypofunction.

NATA Accreditation No 2178

Tests Completed: LH(s), FSH(s), Oest(s), Commenting, B12(s), Fol(s), LFT(s),
C(s), UCreat(s), E(s), Glu(p), Lipids HDL(s), Vit D(s),
TSH(s), Active B12(s), FBC(e)

Tests Pending :

Sample Pending :

Next time - Need iron + Zin

Patient Name: CELEBIOGLU, AYLIN
Patient Address: 19 PANORAMA CRESCENT, MOUNT RIVERVIEW 2774
D.O.B: 7/06/1982
Medicare No.: 2539340408
Lab. Reference: 838481429-C-C205
Addressee: DR CECILIA ROWE
Gender: F
IHI No.:
Provider: bsp
Referred by: Dr Cecilia Rowe
Date Requested: 29/02/2024
Date Collected: 2/03/2024
Specimen:
Subject(Test Name): LIPIDS HDL(S)
Clinical Information:

Date Performed: 2/03/2024
Complete: Final

Clinical Notes : ON MIRENA

Date	03/12/19	02/09/21	26/03/22	02/03/24		
Time F-Fast	0824 F	1017 F	0922 F	1016 F		
Lab ID	841591424	864192056	847455944	838481429	Units	Reference
Status	Fasting	Fasting	Fasting	Fasting		
Cholesterol	4.0	L 3.7	4.0	4.6	mmol/L	(<5.5)
Triglycerides	0.8	0.6	0.5	0.7	mmol/L	(<2.0)
HDL Chol.	1.6	1.8	2.0	1.8	mmol/L	(>1.2)
LDL Chol.	2.0	L 1.6	1.8	2.5	mmol/L	(<3.0)
Non-HDL Chol.				2.8	mmol/L	(<4.0)

Comments on Collection 02/03/24 1016 F:
 Please note that the above reference limits are decision limits.
 A flag based on these limits is an indication to review the absolute
 cardiovascular risk for the patient. For assessment of absolute
 cardiovascular disease risk please see www.cvdcheck.org.au

The above decision limits are based on the European Atherosclerosis Society
 (EAS) and European Federation of Clinical Chemistry and Laboratory Medicine
 (EFLM) Consensus Statement 2016 and the Australasian Association of
 Clinical Biochemistry and Laboratory Medicine (AACB) Lipid Reporting
 Guideline 2018.

Lipid treatment targets for patients at high risk of cardiovascular disease:

Total cholesterol	<4.0 mmol/L
Triglyceride	<2.0 mmol/L
HDL cholesterol	>1.0 mmol/L
LDL cholesterol	<2.5 mmol/L (<1.8 mmol/L for very high risk)
Non-HDL cholesterol	<3.3 mmol/L (<2.5 mmol/L for very high risk)

High risk - Primary prevention Very high risk - Secondary prevention

Target values from the AACB Lipid Reporting Guideline 2018.

Please note that as there is a continuum of risk, benefits are obtained for
 any measured lipid components moving towards and beyond the various target
 levels.

NATA Accreditation No 2178

Tests Completed: LFT(s), C/s, UCreat(s), F(s), Glu(s), Chol(s), HDL(s), LDL(s), Non-HDL(s), TG(s)